Amit K. Verma

https://einsteinmed.edu/labs/amit-verma/

Focalización de la transducción de señales en neoplasias hematológicas: 
Las citocinas desempeñan papeles importantes en la regulación de la hematopoyesis normal y se requiere un equilibrio entre las acciones de los factores de crecimiento hematopoyéticos y los factores mielosupresores para la producción óptima de diferentes linajes de células hematopoyéticas. Los síndromes mielodisplásicos (SMD) son conjuntos de enfermedades hematológicas heterogéneas caracterizadas por citopenias refractarias debido a una hematopoyesis ineficaz. Estos trastornos preleucémicos son causas comunes de anemia en los ancianos y su incidencia está aumentando rápidamente. También hemos demostrado que las vías de la superfamilia TGF-beta/smad, IRAK y MAP quinasa están sobreactivadas en los SMD. Nuestro trabajo ha dado lugar a ensayos clínicos con Luspatercept, Galunisertib, CA4948, ARRY-614 y varios otros agentes prometedores en los SMD. Estamos tratando de estudiar los mecanismos moleculares que conducen a la activación de estas vías en los SMD y estamos utilizando inhibidores de moléculas pequeñas en modelos de ratón para dirigirnos a estas vías.

Tratamiento de células madre y progenitoras aberrantes en neoplasias mielodisplásicas:
Hemos demostrado que las células madre aberrantes persisten durante las remisiones morfológicas y están implicadas en las recaídas. Hemos identificado nuevos objetivos contra las células madre de SMD/LMA que se están probando en varios estudios. También estamos realizando análisis epigenéticos y de secuenciación de células madre humanas altamente purificadas y evaluando el papel de estas alteraciones en la transformación de SMD a LMA.

Análisis epigenómico de tumores:
Utilizamos ensayos de alto rendimiento para analizar la metilación del ADN en todo el genoma y hemos optimizado estos ensayos para que funcionen con pequeñas cantidades de ADN. Hemos utilizado con éxito estos ensayos para realizar un análisis integrador de alteraciones epigenéticas y genéticas en varios modelos tumorales, incluidos el síndrome mielodisplásico, el cáncer de esófago, el cáncer de páncreas y el cáncer de células renales.

Estudios clínicos en síndromes mielodisplásicos:
We have a “center of excellence” clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.

1. Un régimen semanal de dosis baja de decitabina y venetoclax es eficaz y menos mielotóxico en una cohorte racialmente diversa.
   Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, Verma A.
   Blood. 24 de septiembre de 2024. PMID: 39316768
2. Inhibición de la glutaminasa en combinación con azacitidina en síndromes mielodisplásicos: ensayo clínico de fase 1b/2 y análisis correlativos.
   DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, García-Manero G, Tiziani S, Verma A*, Konopleva M*.
   Cáncer natural. 19 de septiembre de 2024. PMID: 39300320
   *CoCorrespondiente
3. La restricción farmacológica de los sitios de unión genómica redirige la actividad del factor de transcripción pionero PU.1.
   Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, Verma A, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U.
   Nat Genet18 de septiembre de 2024. PMID: 39294495
4. Los defectos de elongación de la transcripción vinculan las mutaciones oncogénicas de SF3B1 con alteraciones dirigibles en el panorama de la cromatina.
   Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, Verma A, Neugebauer K. M., Pillai MM. Célula Mol18 de abril de 2024;84(8):1475-1495.e18.PMID: 38521065
5. Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN^, Parekh S^, Verma A ^ Las células de leucemia linfoblástica aguda resistentes a la inmunoterapia muestran una expresión reducida de CD19 y CD22 y dependencia de la vía BTK JCI, 20 de febrero de 2024 PMID: 38376944
6. Thakkar A, Pradhan K, Duva B, Carreño JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, Verma A*, Halmos B* Study of efficacy and longevity of immune response to 3rd and 4th doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial Elife 2023, Mar 28;12:e83694. PMID: 36975207
7. Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Decitabina/venetoclax en dosis bajas, no citotóxico y metabólicamente optimizado semanalmente en SMD y leucemia mieloide aguda. Clin Cancer Res. 1 de agosto de 2023;29(15):2774-2780. PMID: 37341641.
8. Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, Verma A *. La activación de la señalización inmunitaria inflamatoria dirigida se observa en los síndromes mielodisplásicos con mutaciones SF3B1. Elife . 30 de agosto de 2022; 11: e78136. PMID: 36040792; PMCID: PMC9427103.
9. Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, Verma A. Alta carga de hematopoyesis clonal en socorristas expuestos al desastre del World Trade Center. Nat Med . 7 de marzo de 2022. PMID: 35256801.
10. Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, Verma A. Impacto de COVID-19 en la tasa de letalidad de pacientes con cáncer durante la ola Omicron. Célula cancerosa. 22 de febrero de 2022: PMID: 35219358; PMCID: PMC8860706
11. Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, Verma A *, Halmos B*. *Eficacia correlativa de las dosis de refuerzo para aumentar las respuestas inmunitarias menguantes a la vacuna contra la COVID-19 en pacientes con cáncer. Cancer Cell . 10 de enero de 2022;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.
12. Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 Feb 26. PMID: 35220402.
13. Pinho S, Wei Q, Maryanovich M, Zhang D, Balandrán JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK, Verma A, Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. Nat Cell Biol. 2022 Feb 24. PMID: 35210567.
14. Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, Verma A, Greally JM, Raj SM, Goel S, Ali SM. Genómica del cáncer colorrectal en poblaciones con ascendencia africana y europea. Cancer Discov. 17 de febrero de 2022: PMID: 35176763.
15. Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, Verma A*, Luo M*, Zhao X*. La metilación de la fosfatasa 4 de especificidad dual controla la diferenciación celular. Cell Rep. 27 de julio de 2021;36(4):109421. PMID: 34320342. *Co-correspondiente.
16. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A*, Halmos B*. Tasas de seroconversión tras la vacunación contra la COVID-19 entre pacientes con cáncer. Cancer Cell . 5 de junio de 2021: PMID: 34133951; PMCID: PMC8179248. *Co-correspondiente
17. Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, Verma A, Steidl U. MDMX actúa como un mecanismo generalizado de transición de leucemia mieloide preleucémica a aguda. Célula cancerosa . 12 de abril de 2021;39(4):529-547.e7. PMID: 33667384.
18. Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, Verma A, Bowman TV Los bucles R excesivos desencadenan una cascada inflamatoria que conduce a una mayor producción de HSPC Dev Cell, 2021, 8 de marzo; 56(5): 627-640. PMID: 33651979.
19. Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Verma A, Braunschweig I, Goldfinger M. Seguridad de axicabtagene ciloleucel para el linfoma de células B grandes recidivante/refractario en una población interurbana de edad avanzada. Trasplante de médula ósea . 2021 Jul;56(7):1761-1763. PMID: 33846558.
20. Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy Nature Cancer, 2021, 2: 392–399.
21. Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, Verma A* . Tasa de letalidad de pacientes con cáncer y COVID-19 en un sistema hospitalario de Nueva York. Cancer Discov . 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.
22. Lista AF, Sun Z, Verma A*, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomida-epoetina alfa versus lenalidomida-monoterapia en síndromes mielodisplásicos refractarios a la eritropoyetina recombinante JCO, 2021, 13 de enero: PMID: 33439748 *Correspondiente.
23. Consorcio de COVID-19 y cáncer. Un marco sistemático para obtener rápidamente datos sobre pacientes con cáncer y COVID-19: gobernanza, protocolo y garantía de calidad del CCC19. Cancer Cell . 14 de diciembre de 2020;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.
24. Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; Consorcio COVID-19 y Cáncer. Impacto clínico de COVID-19 en pacientes con cáncer (CCC19): un estudio de cohorte. Lancet . 20 de junio de 2020;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.
25. Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Base biológica de la eficacia de las trampas de ligandos de receptores activadores en síndromes mielodisplásicos. J Clin Invest. 3 de febrero de 2020;130(2):582-589. doi: 10.1172/JCI133678. Revisión. PMID: 31961337
26. Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan 9;382(2):140-151. PMID: 31914241
27. Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C, Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*, Verma A*. La reprogramación epigenética mediada por lactato regula la formación de fibroblastos asociados al cáncer de páncreas Elife, 30 de octubre; 8 de octubre de 2019, (en prensa)* Contribución igual PMID: 31663852
28. Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. PMID: 31481511
29. Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Salomonis N, Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D*
    Las mutaciones U2AF1 inducen vías inmunes innatas oncogénicas al regular la expresión de isoformas activas de IRAK4 en neoplasias hematológicas. Biografía de Nature Cell Mayo de 2019;21(5):640-650 * Contribución igualitaria
30. Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,*Wickrema A*
    Fosforilación y activación reguladas por citocinas de TET2 por JAK2 en la hematopoyesis Descubrimiento del cáncer 2019 Jun;9(6):778-795 * Contribución igualitaria
31. Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C, Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*, Verma A*. La reprogramación epigenética mediada por lactato regula la formación de fibroblastos asociados al cáncer de páncreas Elife, 30 de octubre; 8 de octubre de 2019, (en prensa)* Contribución igual PMID: 31663852
32. Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Sep 3. PMID: 31481511
33. Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Salomonis N, Walter M, Komurov K, Boultwood J*, Verma A*, Starczynowski D*
    Las mutaciones U2AF1 inducen vías inmunes innatas oncogénicas al regular la expresión de isoformas activas de IRAK4 en neoplasias hematológicas. Biografía de Nature Cell Mayo de 2019;21(5):640-650 * Contribución igualitaria
34. Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C, Verma A,*Wickrema A*
    Fosforilación y activación reguladas por citocinas de TET2 por JAK2 en la hematopoyesis
    Descubrimiento del cáncer 2019 Jun;9(6):778-795 * Contribución igualitaria
35. Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A *, Steidl U*Progresión del síndrome mielodisplásico a leucemia mieloide aguda a nivel de células madre Nature Medicine 2018, enero;25(1):103-110 * Contribución igual
36. Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, LF Cole, S. Bhagat, TD Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, VJ Wickrema, A. Ye, BH Frank, DA Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, AR Epling-Burnette, PK Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B. Verma, A. El inhibidor antisentido de STAT3 disminuye la viabilidad de las células madre mielodisplásicas y leucémicas. J Clin invertir . 25 de septiembre de 2018. PMID: 30252677
37. Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A*, Ye BH*, Janakiram M.* La ATLL norteamericana tiene un perfil mutacional y transcripcional distintivo y responde a terapias epigenéticas. Blood. 13 de agosto de 2018. PMID: 30104217 * Contribución igualitaria
38. Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A*, Prezant DJ* Mieloma múltiple y su enfermedad precursora entre los bomberos expuestos al desastre del World Trade Center JAMA Onc, 1 de junio de 2018;4(6):821-827. PMID: 29710195 * Contribución igual
39. Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Estimulación independiente del receptor de trombopoyetina del tallo hematopoyético células por eltrombopag. Ciencia Transl Med . 12 de septiembre de 2018; 10 (458). PMID: 30209246
40. Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK El eje RUNX1/IL-34/CSF-1R es un eje regulado autocrinalmente modulador de la resistencia a la inhibición de BRAF-V600E en melanoma. Perspectiva de la JCI . 25 de julio de 2018;3(14). PMID: 30046005
41. Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Inhibición dual de MDMX y MDM2 como estrategia terapéutica en la leucemia. Ciencia Transl Med . 2018, 11 de abril;10(436). PMID: 29643228
42. Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med. 2018 Jun 4;215(6):1709-1727 PMID: 29773641
43. Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A, “Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,” Genome Res, 2017, Oct 6. PMID: 28986391
44. Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A, “Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,” Cancer Research Jul, 2017, PMID: 28684528
45. Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E. Direct “Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,” Cancer Cell 2017 Oct 9.PMID: 29017059
46. Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., “Pharmacological inhibition of the transcription factor PU.1 in leukemia,” J Clin Invest 2017 Oct 30, PMID: 29083320
47. Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ, Verma A*, Epling-Burnette PK* (*Co-Corresponding), “Efficacy of ALK5 Inhibition in Myelofibrosis.” JCI Insight (In Press)
48. Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K, Verma A*, Susztak K* (*Co-Corresponding), “Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .” JBC 2016, Dec 1. PMID: 2790905
49. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A, “Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.” Cancer Res 2016 Jun 10. PMID: 27287719
50. Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I, Verma A, “High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,” Leukemia 2016 Apr 29. PMID: 27125205
51. Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. “MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.” Nat Commun. 2016 Feb 22;7:10739. PMID: 26898884
52. Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., “Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.” Lancet Haematol. 2015 Oct;2(10):e417-26. PMID: 26686043
53. Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*, Verma A*, Wickrema A*. (*Co-Corresponding), “Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.” PNAS 2015; Nov 17;112(46): PMID: 26578796
54. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U., “New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.’ Nature Chem Biol. 2015 Oct 5. PMID: 26436839
55. PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U, “PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.” Blood. 2015 Jul 13. PMID: 26170031
56. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, “Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.” Br J Haematol. 2015 Jun 24. PMID: 26105212
57. Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E, “Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.” Mol Cell. 2015 Jun 3. PMID: 26051178
58. Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC, “Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.” Mol Cell Biol. 2015 May 26. PMID: 26012550
59. Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma A, Platanias LC, “Central Role of ULK1 in Type I Interferon Signaling.” Cell Reports 2015, Apr 28;11(4):605-17. PMID: 25892232
60. Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A, Jaenisch R, Aifantis I, “TET1 is a tumor suppressor of hematopoietic malignancy.” Nat Immunol. 2015 Apr 13. PMID: 25867473
61. Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*, Verma A*, *co-corresponding authors, “IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.” Blood. 2015, Mar 25. PMID: 25810490
62. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, “Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.” Nat Commun. 2015 Jan 9;6:5901. PMID: 25574665
63. Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER, “Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.” Blood. 2015 Jan 8. PMID: 25573988
64. Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U, “Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.” Nature Medicine, 2015 (In Print)
65. Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A, “Targeting chemokine pathways in esophageal adenocarcinoma.” Cell Cycle. 2014 Nov 1;13(21):3320-7. PMID: 25485576
66. Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A, “Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.” Clin Cancer Res. 2014 Jun 10. PMID: 24916699
67. Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J, Verma A, Prabhakar N, Godley LA, “TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.” Cell Rep. 2014 May 14. PMID: 24835990
68. Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., “Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.” Blood. 2014 Jun 2. PMID: 24891322
69. Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A, “Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.” Leuk Lymphoma, 2014 Dec;55(12):2901-6.PMID: 24650011
70. Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A, Verma A*, Steidl U, *Co-Corresponding, “A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.” Journal of Clinical Investigation 2014 Feb 3 PMID: 24487588
71. Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B, Verma A, Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, “High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.” Oncogene, 2014 Mar 31 PMID: 24681958
72. Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, “Recurrent genetic defects on chromosome 7q in myeloid neoplasms.”Leukemia 2014 Jan 16. PMID: 24429498
73. Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B, Verma A, He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, “Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.” Cell Reports 2013 Dec 24 PMID: 24373966
74. Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M, Verma A, Zheng D, Greally JM, Susztak K, “Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.” Genome Biol. 2013 Oct 7;14(10):R108. PMID: 24098934
75. Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, Jädersten M, Verma A, McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, “Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.” JCO 2013 Oct 1;31(28):3557-64. PMID: 24002510
76. Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK, “Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.” Am J Hematol. 2013 Nov;88(11):E245-9. PMID: 23828763
77. Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma A, Meltzer SJ, Mori Y, “Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.” Gut 2013 Sep 2. PMID: 24000294
78. Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y, Verma A*, Das K, *Co-Corresponding, “High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.” Genes Chromosome Cancer 2013 Oct 3. PMID: 24123713
79. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC, “Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.” JBC, 2013 Aug 16;288(33):23814-22 PMID: 23814052
80. Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J; Verma, A; “Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.” Nucleic Acid Res 2013 Sep;41(16):e157 PMID: 23861445
81. Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U, “Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.” Nat Immunol. 2013 May;14(5):437-45. PMID: 23563689
82. Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A, “miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.” Blood 2013, Apr 11;121(15):2875-81. PMID: 23390194
83. Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A, Verma A, “High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.” JBC 2013 Mar 29;288(13):8805-14. PMID: 23306203
84. Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A*, Singhal S,* Co-Corresponding, “Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.” Journal of Immunology 2013 Mar 15;190(6):2966-75. PMID: 23408834
85. Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J, Verma A*, Meltzer SJ*, Co-Corresponding, “Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett’s Esophagus and Esophageal Adenocarcinoma.” Gastroenterology 2013 May;144(5):956-966. PMID: 23333711
86. Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A, “Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.” Cancer Res, 2012 Dec 27. PMID: 23066032
87. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T, Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A, “Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.” Blood 2012; 120(10):2076-86. PMID: 22753872
88. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, “Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.” Leukemia. 2012 Sep 11. PMID: 23032694
89. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U, “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.” Blood. 2012 Aug 9;120(6):1290-8. PMID: 22723552
90. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP, “Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.” Blood. 2012 Jun 21;119(25):6109-17. PMID: 22553315
91. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U., “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.” Blood. 2012 May 24. PMID: 22627766
92. Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A., “Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.” Leuk Lymphoma.2012 Apr 18. PMID: 22448921
93. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR, “Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.” Haematologica. 2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540
94. Sharma B, Altman JK, Goussetis DJ, Verma AK, Platanias LC, “Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.” J Biol Chem. 2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535
95. Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A, “Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.” J Biol Chem. 2011 Apr 30. PMID: 21532034
96. Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A, Verma A, “Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.” PLOS Genetics 2011 Mar;7(3) PMID: 21483804
97. L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol, G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and A Verma, “Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.” Cancer Research 2011 Feb 1;71(3):955-63.PMID: 21189329
98. Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma Alaska, Fish EN, Platanias LC, “Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.”
    Revista de Biología Química. 25 de febrero de 2011;286(8):6017-26.PMID: 21149447
99. Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, Platanias LC, “Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.” J Biol Chem. 2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.
100. Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A*, Das B, “Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.”
     Linfoma de Leuk. Junio de 2010;51(6):1108-14. PMID: 20536349
101. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP, “Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.” Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. PMID: 20095039
102. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, Norbury C Hellström-Lindberg E, Wainscoat JS, Boultwood J, “Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.” Leukemia. 2010 Apr;24(4):756-64. PMID: 20220779
103. Einstein F, Thompson RF, Bhagat TD, Fazzari MJ, Verma A, Barzilai N, Greally JM, “Cytosine methylation dysregulation in neonates following intrauterine growth restriction.” PLoS One. 2010 Jan 26;5(1):e8887 PMID: 20126273
104. Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E., Verma A., Suzuki M., Greally J.M., “High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.” Nucleic Acids Res. 2009 Jul;37(12):3829-39. PMID: 19386619
105. Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM, Verma A, “Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.” PLOS One 2008 Aug 13;3(8):e2965 PMID: 18698424
106. Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A, Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M, Verma A, “Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.” Blood 2008 Oct 15;112(8):3434-43 PMID: 18474728
107. Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A, Verma A, “Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.” Leukemia and Lymphoma 2008 Oct;49(10):1963-75
108. Zhou L, Opalinska J, Verma A, “p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.” Cell Cycle 2007, 1;6(5):534
109. Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS, Verma A, “Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.” Blood 2006, 15;108(13):4170-7
110. Verma A, and List A, “Cytokine Targets in Myelodysplastic syndromes.” Current Hematology Reports 2005 Nov;4(6):429-35
111. Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN, “Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.” Proc Natl Acad Sci USA. 2003 Nov 11;100(23):13453-8
112. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, “Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.” Bone Marrow Transplant. 2003 May;31(9):813-6.
113. Verma A., Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., “Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.” Journal of Biological Chemistry 22;277(47):44988-95
114. Verma A, Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., “Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.” Journal of Immunology 2002, 168 (12) (Cutting edge section)
115. Verma A, Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, “Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.” Journal of Biological Chemistry 2002, 277(10):7726-35
116. Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W and Van Besien K, “Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.” Blood 2002, 99(6):2255-8

Artículos de revisión

1. Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A, “Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.” Leukemia, 2015 (In Press)
2. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A., "Papel de la metilación del ADN en el carcinoma de células renales". J Hematol Oncol. 22 de julio de 2015;8(1):88. PMID: 26198328
3. Verma A, Steidl U., “A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.”
   Medicina Natural. 2015;21:113-4. Identificador de la publicación: 25654599
4. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes." Leukemia. 2015 Mar 12. PMID: 25761935
5. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y., "Impacto de la sobrecarga de hierro y beneficio potencial de la quelación del hierro en el síndrome mielodisplásico de bajo riesgo". Blood, 7 de agosto de 2014;124(6):873-81. PMID: 24923296
6. Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK, Evans T., "Vías de señalización del ácido retinoico en el desarrollo y las enfermedades".
   Bioorg Química Médica. 15 de enero de 2014;22(2):673-83. PMID: 24393720
7. Elias HK, Schinke C, Bhattacharyya S, Will B*, Verma A*, Steidl U* *CoCorresponding, “Stem cell origin of myelodysplastic syndromes.” Oncogene 2013 Dec 16. PMID: 24336326
8. Pathak S, Roth M, Verma A*, Steidl U*. *CoCorresponding, “Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.”
   Opinión de expertos sobre el fármaco Metab Toxicol. Diciembre de 2013;9(12):1667-75. PMID: 24215532
9. Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK, “Linked-in: design and efficacy of antibody drug conjugates in oncology.” Oncotarget 2013 Mar;4(3):397-412. PMID: 23651630
10. Khan H, Vale C, Bhagat T, Verma A.,   “Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.”
    Hematol de semen. Enero de 2013;50(1):16-37. PMID: 23507481
11. Elías H, Verma A,  “Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.”
    Linfoma de Leuk. Diciembre de 2012;53(12):2337-8. PMID: 22897726
12. Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A., “Alterations in the ribosomal machinery in cancer and hematologic disorders.” J Hematol Oncol. 2012 Jun 18;5:32. PMID: 22709827
13. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A., “Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.” Int J Clin Exp Pathol. 2012;5(5):382-96. PMID: 22808291
14. Sharma A, Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM, Verma A, “DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.” WIREs Systems Biology and Medicine 2010 Nov-Dec;2(6):654-69. PMID: 20890963
15. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM, Verma A, “Aberrant DNA methylation in malignant melanoma.” Melanoma Research 2010, Aug; 20(4):253-65 PMID: 20418788
16. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A., “Mechanism of action of lenalidomide in hematological malignancies.”
    J Hematol Oncol. 12 de agosto de 2009;2:36
17. Opalinska J, Zhou L, Verma A., “A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.” Leukemia Research (Commentary) 2007, 48(3):443
18. Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P, Verma A., “Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.” Journal of Interferon and Cytokine Research 2007, 27(7):543
19. Mohindru M, Verma A, “Engineered antibodies act as targeted therapies in cancer treatment.” Indian Journal of Pediatrics, 2005 Nov;72(11):943-7
20. Sassano A, Verma A, Platanias LC, "Vías de la proteína quinasa activada por mitógeno en la señalización del interferón". Methods Molecular Medicine, 2005;116:135-50.
21. Mohindru M, Verma A, "Los inhibidores de la quinasa traducen los descubrimientos de laboratorio en nuevas y apasionantes curas para el cáncer". Indian Journal of Pediatrics, agosto de 2004;71(8):713-8.
22. Verma A, Kambhampati S, Parmar S, Platanias LC, “Jak family of kinases in cancer.” Cancer Metastasis Rev. 2003 Dec;22(4):423-34.(rev)
23. Verma A, and Platanias LC, “Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.” Leukemia and Lymphoma 2002, 44:703-709
24. Verma A, and Stock W, “Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.” Current Opinion in Oncology, 2001, 13:14-20
25. Verma A, and Gupta YK, “The search for a super oral rehydration solution (0RS).” Drugs: News and Views, 1995, 3(2):129-132.